Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. - Wikidata - awgldk - TriplyDB

Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.

Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.

http://www.wikidata.org/entity/Q36936139

about

Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma Ephs and Ephrins in malignant gliomas Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.Glial progenitors as targets for transformation in glioma.Molecular profiling of childhood cancer: Biomarkers and novel therapies Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.Therapeutic targeting of platelet-derived growth factor receptors in solid tumors.Diffuse intrinsic pontine glioma: a reassessment.The genetic signatures of pediatric high-grade glioma: no longer a one-act play.Management of diffuse intrinsic pontine glioma in children: current and future strategies for improving prognosis.Molecular biology of pediatric brain tumors and impact on novel therapies.Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors.Managing teenage/young adult (TYA) brain tumors: a UK perspective.Oral Targeted Therapies and Central Nervous System (CNS) Metastases.Investigational new drugs for brain cancer.Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma.MRI Evaluation of Non-Necrotic T2-Hyperintense Foci in Pediatric Diffuse Intrinsic Pontine Glioma.Potential role of tyrosine kinase inhibitors during primary HIV-1 infection.The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition Children with minimal chance for cure: parent proxy of the child's health-related quality of life and the effect on parental physical and mental health during treatment.Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.CDK4/6 and PDGFRA Signaling as Therapeutic Targets in Diffuse Intrinsic Pontine Glioma.Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.Targeting Oncogene-Induced Autophagy: A New Approach in Cancer Therapy?

P2860

Q26801528-036511A0-98D7-44AD-AFDF-B1A65A573DD2 Q27015780-641A97F3-D90C-4C5A-8CE4-E92D72C64F2B Q27317083-AB877D91-4C6B-4E16-8B26-DB60FB9F88AF Q34359662-512C0F4F-B997-42AC-8C04-AAEAB4F85D1A Q34735661-4879E9C6-02A9-4FEF-BC62-8B70F58E4113 Q36250783-E3C740AB-9D14-4BB7-8F93-F8E21936B6B3 Q36600202-B3C033E4-4B6C-4849-8433-717528FC3F61 Q36918220-50E601DF-B857-4164-91F0-5C738B8305E8 Q38160946-B28AE80B-AD2E-485B-8271-439E52689ACB Q38208998-8E953CFB-6259-4877-A2B2-0693A2AC023A Q38248990-C10A4C52-253F-49B9-AAE7-BF2C99528017 Q38273428-24DE311B-C0D2-4709-9F74-642875967D09 Q38359284-68310CB0-DA50-4207-9D96-8520B59FA110 Q38363549-177349F5-8F13-4033-A01A-8DC6658EBF40 Q38539466-D626F0BD-2460-4663-9940-08E099EBC788 Q38631975-D1B4E525-5AF7-4DE8-B351-E85C807146C3 Q38832510-3C83FC04-97CF-41B6-9229-831EF28E832B Q38926034-71FFEFC1-DC37-4692-A193-0A5057E37123 Q39752215-E769F464-27EB-4AF4-BD61-16EA41592DA6 Q40283574-4E3F315B-9940-4CC4-B6A8-F4AAED91B3DE Q41470815-A9DA77DA-DD84-4682-8168-A37AE51C03F3 Q47140927-2FCFEF53-18AE-48AA-BC7B-14D755557795 Q47955352-3FFC90CC-7DAA-4900-AE85-EABB97A3D8FC Q49244147-984F7AE4-9FBF-4EF5-BA3C-A991F4EF9C99 Q50091855-92601543-37B6-42D1-B0B2-265EB51A9DB4 Q51744172-271C4A00-8D2C-42BF-9718-1A207AD05048 Q55351090-7035D002-2CD9-4FA8-BCEF-60C50C735A10 Q55456561-041B4B48-8971-4C4B-9274-6A50FDF40E7F Q58919591-73851088-6A38-4906-95F1-C24AEE19B0D4

P2860

Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.

http://www.wikidata.org/entity/Q36936139

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Phase I trial, pharmacokinetic ...... fuse intrinsic pontine glioma.

@en

type

label

Phase I trial, pharmacokinetic ...... fuse intrinsic pontine glioma.

@en

prefLabel

Phase I trial, pharmacokinetic ...... fuse intrinsic pontine glioma.

@en

P1433

Q36936139-335346D1-6829-4A53-959C-7329AD8A6BD6

P1476

Q36936139-F83948F1-28B0-430A-A882-F4B311903168

P2093

Q36936139-03B70A96-8C64-42BB-AC1A-356A30E1EED7

Q36936139-078222F3-4A08-4BE5-BC61-65733261B640

Q36936139-146D0AFE-DA9A-4717-96E2-C7DFB47B3DBA

Q36936139-20A75840-F586-4275-9CF1-8F2F6BC0F2C9

Q36936139-348079DE-CD3A-4DFF-A2BC-4AFD9D050F0C

Q36936139-3BABA7DE-9517-4232-8B88-D1B04CDC737C

Q36936139-3DA54A61-EBAE-43C9-8A23-4D692F03DFF1

Q36936139-4A254D1B-DD7A-4D5A-A781-56641343F8C5

Q36936139-4B675AC4-9705-4B5B-B374-3CE22D801736

Q36936139-51158959-3404-4DC5-BEA2-A57D071740EE

P2860

Q36936139-13ED0B76-69A1-4A1C-8F3E-8F5F573DD30D

Q36936139-1B260B1F-9C87-4768-8162-775B1BD4F657

Q36936139-1BF79518-6EA9-4797-AE99-E2BA98690E00

Q36936139-1CB74F04-53C4-4409-844A-6DE218D9CA95

Q36936139-1F04B8A7-C48E-42E2-AEE0-348CE1BD881A

Q36936139-22033E31-5EFA-4D99-8CEC-B3B910375C36

Q36936139-27AC722A-09A1-4778-8894-4E2EE7FA84B1

Q36936139-2B576A0A-A4E1-4C11-90E8-29E81F1F049D

Q36936139-3A1B1F45-D927-4408-A89C-31D3EFA40BE7

Q36936139-3AC10DE7-22B4-49C8-BF08-89474146DB45

P304

Q36936139-8B4A1C7A-3A42-4793-9B0C-E6B7D8DD80F6

P31

Q36936139-FB5DEA86-89E0-4F63-BB8D-F2F7023080C2

P356

Q36936139-F30D2D9B-BF0B-4608-9C0A-F05E571423BA

P407

Q36936139-48527B97-C3C3-4D06-B6D3-DFD0564A77CB

P433

Q36936139-1B172F1C-EA45-4A7A-8BD4-6571D1553BF4

P478

Q36936139-CE992A99-FC81-4766-8573-A6CE210C74A7

P50

Q36936139-2136CDAE-7FD2-4B46-B057-C60425EB2F7E

Q36936139-F769E877-3700-4EDA-AD78-88750946B5CB

P577

Q36936139-15BD9AED-F65B-4086-9323-0E635F414E66

P698

Q36936139-3902539A-ACCE-4D12-87EE-A27BE888BD4F

P921

Q36936139-A11E2CD7-0320-48EC-811C-11EC6F8BDFCD

Q36936139-CEBB9FC0-7006-43BE-8959-1BA8263BE302

P932

Q36936139-99C0EB30-019C-4BB0-B20D-9AC976F5E708

P356

1078-0432.CCR-13-0306

P1433

Clinical Cancer Research

P1476

Phase I trial, pharmacokinetic ...... fuse intrinsic pontine glioma.

@en

P2093

Amar Gajjar

http://www.w3.org/2001/XMLSchema#string

Andrew M Davidoff

http://www.w3.org/2001/XMLSchema#string

Arzu Onar-Thomas

http://www.w3.org/2001/XMLSchema#string

Atmaram S Pai Panandiker

http://www.w3.org/2001/XMLSchema#string

Clinton F Stewart

http://www.w3.org/2001/XMLSchema#string

Cynthia Wetmore

http://www.w3.org/2001/XMLSchema#string

Jie Huang

http://www.w3.org/2001/XMLSchema#string

John C Panetta

http://www.w3.org/2001/XMLSchema#string

Justin N Baker

http://www.w3.org/2001/XMLSchema#string

Sue C Kaste

http://www.w3.org/2001/XMLSchema#string

P2860

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function

Diffuse brainstem glioma in children: critical review of clinical trials.

Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.

PDGF-C induces maturation of blood vessels in a model of glioblastoma and attenuates the response to anti-VEGF treatment.

Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.

Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas.

Prospective collection of tissue samples at autopsy in children with diffuse intrinsic pontine glioma.

Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.

P304

3050-3058

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-13-0306

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Alberto Broniscer

Sharyn D. Baker

P577

2013-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23536435

http://www.w3.org/2001/XMLSchema#string

P921

diffuse intrinsic pontine glioma

phase I clinical trial

P932

3685168

http://www.w3.org/2001/XMLSchema#string